Chronic fatigue syndrome — all decisions

The Board remands the claims for further development, including obtaining additional medical evidence and examinations.

The Board remands the claim for a new VA examination to determine the nature and likely etiology of chronic fatigue syndrome (CFS), as the December 2023 VA medical opinion is deemed inadequate.

The appeal for service connection for bilateral hearing loss and hypertension was dismissed, while the claims for chronic fatigue syndrome, bilateral pes planus, left foot cuts, right foot cuts, fibromyalgia, left knee osteoarthritis, a right knee disorder, and obstructive sleep apnea were remanded for further development.

The appeal of the January 2024 proposal to reduce the disability rating from 30 percent disabling to 10 percent for coronary artery disease is dismissed. The Board also denied service connection for various conditions, including chronic fatigue syndrome and posttraumatic stress disorder with traumatic brain injury residuals.

The Board denied service connection for chronic fatigue syndrome and fibromyalgia, finding that the evidence does not support a current diagnosis of these conditions. The low back disorder was remanded for further development.

The veteran withdrew the appeal for all issues, including higher disability evaluations and service connection claims.

The Board denied service connection for chronic fatigue syndrome and remanded the claims for a left hand disability and right hand disability to afford the Veteran a VA medical opinion.

The Board granted service connection for chronic fatigue syndrome, finding the evidence to be in approximate balance as to whether it was related to the Veteran's period of active service.

The Board dismissed the Veteran's appeal for not timely submitting a Notice of Disagreement (NOD) within one year from the date of the mailing of an adverse decision.

The Board dismissed the appeals for service connection for migraines and chronic fatigue syndrome due to a concurrent election of review options.

The Board remands the issues of entitlement to service connection for chronic fatigue syndrome and gastroesophageal reflux disease for further development, including obtaining a VA medical opinion.

The veteran withdrew his appeal for all 11 issues, and the Board has no jurisdiction to review these matters.

The Veteran withdrew his appeal, and the Board dismissed all issues.

The Board denied service connection for chronic fatigue syndrome, insomnia, and a respiratory condition. The claims for fibromyalgia, numbness in the left arm, numbness in the right arm, radiculopathy of the left lower extremity sciatic nerve, radiculopathy of the right lower extremity sciatic nerve, and headache condition were remanded for further development.

The Board granted restoration of a 30 percent rating for iron deficiency anemia effective December 6, 2021, and initial ratings of 70 percent and 60 percent for the same condition, respectively. The rating in excess of 60 percent was denied.

The Veteran's appeal for service connection for GERD was granted, while the claims for sleep apnea, chronic fatigue syndrome, and a headache condition were denied.

The Board granted service connection for obstructive sleep apnea and denied claims for service connection for chronic fatigue syndrome, sinusitis, and increased ratings for depression. The decision also remanded the claim for service connection for erectile dysfunction.

The Board granted an earlier effective date of May 28, 2008, for the award of service connection for chronic fatigue syndrome (CFS) and denied earlier effective dates for obstructive sleep apnea and erectile dysfunction.

The Veteran's service connection for bilateral hearing loss was granted, while claims for other conditions such as chronic fatigue syndrome, headaches, a heart disorder, hypertension, irritable colon syndrome, kidney removal, kidney cancer, liver disorder, lung disorder, renal disease, sleep apnea, stomach disorder, and stress disorder were denied.

The Board granted an increased initial rating of 60 percent for chronic fatigue and ulcerative colitis, effective February 8, 2022, while denying increased ratings for migraine headaches and OSA.